Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02250326
Title Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications

lung non-small cell carcinoma

Therapies

Azacitidine + Nab-paclitaxel

Nab-paclitaxel

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.